Cost-effectiveness acceptability curve and cost-effectiveness thresholdsZONG Xin, SUN Li-hua2222-2225,2296
Commentary on compatibility of drug products and their container systemsHUO Xiu-min, MA Yu-nan, JIANG Yu2226-2229,2325
Drug interaction potential of oral baicalein on metabolic enzymes in ratsTIAN Shuo, HE Guo-rong, GAO Mei, SUN Jia-lin, WANG Su-bo, DU Guan-hua2230-2234,2301
In vitro herb-drug interaction mediated by CYP3A4 and its potential application in the treatment of AIDSMAO Yu-chang, WANG Jun, SUN Yi, CHOU Gui-xin, HU Zhuo-han2235-2240
Review of the R&D and technology innovation of epothilones as new drugsYAN Jia-qi, DAI Hong-ming2241-2249
Progress in the research of anti-tuberculosis drugsWANG Shuai, WANG Jing, LI Qing, ZHANG Hui-bin, ZHOU Jin-pei2250-2256,2271
Research progress of boron-containing compounds as anti-infective drugsLI Qing, ZHOU Jin-pei, WANG Shuai, ZHANG Hui-bin2257-2264
Selective melatoninergic ligands for MT2 subtype receptorWAN Ning, JU Jia, LIU Dao-zhou, DU Jiang-bo, ZHOU Si-yuan, ZHANG Bang-le2265-2271